The West Yorkshire, UK-based firm says the system runs from one cylinder of mixed gas and there are separate cycles to prepare anaerobic or microaerobic conditions. It takes less than two minutes and about 18p to create an anaerobic environment, and just 15 seconds and less than 3p to achieve microaerobic conditions.
According to the company, laboratories with low sample throughput can justify this system as a compact and cost-effective alternative to a workstation.
Using the Whitley jar gassing system also eliminates chemical waste and reduces condensation so that samples can be handled and read more easily following incubation, the company says.
Optional accessories include adaptor kits for reusing existing anaerobic jars.
Jar gassing system gains a colour touch screen
And an optional printer for traceability, auditing and accreditation
You may also like
Manufacturing
UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure
Read moreA new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Trending Articles
You may also like
Manufacturing
Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform
The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
Manufacturing
Symbiosis completes full ICH climatic zone coverage with new stability chamber addition
Sterile injectable CDMO Symbiosis Pharmaceutical Services has installed a 30°C stability chamber at its Stirling facility, completing its coverage of all four ICH-defined climatic zones and strengthening its commercial drug product supply capabilities for global markets
Manufacturing
Simplifying continuous operations: lowering the barrier to faster development
Continuous manufacturing has long promised faster development, improved process understanding and, in the absence of scale-up, smoother commercialization. For many pharmaceutical R&D teams, those benefits are well understood. What still holds them back, however, is not scepticism about the concept; it’s the perceived effort required to implement it